Formula Pharmaceuticals
Formula Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Formula Pharmaceuticals.
Formula Pharmaceuticals is a company.
Key people at Formula Pharmaceuticals.
Key people at Formula Pharmaceuticals.
Formula Pharmaceuticals, Inc. was a privately held, immuno-oncology company based in Berwyn, Pennsylvania, focused on developing CAR immunotherapy for oncology and autoimmune diseases using a proprietary non-viral, allogeneic CIR-CIK (Cytokine Induced Killer) technology platform.[1][4] This platform aimed to improve upon existing CAR-T approaches by enhancing patient access, clinical benefits, and manufacturing cost-effectiveness, targeting hematologic cancers like acute lymphoblastic leukemia and solid tumors.[1][2] The company served patients with unmet needs in oncology, addressing limitations of autologous CAR-T therapies that rely on viral transduction and patient-specific cells, but it merged into CoImmune, Inc. in 2020, ceasing independent operations.[2][3][4]
Founded in 2009 and headquartered in Berwyn, PA, Formula Pharmaceuticals emerged as a biotech innovator in the immuno-oncology space.[4] Specific founders and early backstory details are not detailed in available sources, but the company quickly advanced a non-viral Sleeping Beauty transposon-based gene transfer system for CAR-CIK cells.[1] A pivotal moment came in its strategic collaboration with the Max Delbrück Center for Molecular Medicine (MDC), securing an exclusive license for MDC's SB100X transposase to develop CIK-based CAR immunotherapies.[1] This partnership highlighted early traction in allogeneic cell therapies, culminating in the 2020 merger with CoImmune, accompanied by a $6 million investment to advance the CAR-CIK program.[2][3]
Formula stood out in the crowded CAR therapy field through these key advantages:
Post-merger, these assets integrated into CoImmune's portfolio, enhancing its immuno-oncology offerings.[2][3]
Formula rode the explosive growth of cell therapies in the 2010s, capitalizing on CAR-T approvals like Kymriah and Yescarta while addressing their key pain points—high costs, manufacturing complexity, and limited scalability.[1][2] Its timing aligned with the shift toward allogeneic platforms, as market forces favored "off-the-shelf" solutions amid rising demand for accessible cancer immunotherapies.[2] By merging into CoImmune, Formula influenced the ecosystem by broadening pipelines (e.g., combining with CoImmune's CMN-001 dendritic cell therapy), fostering South Korean-US biotech synergies via SCM Lifescience and Genexine funding, and advancing CIK-based tech toward FDA trials in renal carcinoma and leukemia.[2][3] This contributed to the evolution of next-gen CARs, reducing reliance on patient-derived cells.
Formula's legacy endures through CoImmune, which absorbed its CAR-CIK platform to pursue Phase 2b trials for CMN-001 in renal carcinoma and CIK therapies in leukemia, backed by recent investments.[2][3] Next steps likely involve clinical readouts, pipeline expansion into solid tumors, and potential FDA milestones, shaped by trends like non-viral engineering and combo immunotherapies. As allogeneic CARs mature, CoImmune's integrated assets position it to capture market share in a sector projected to grow amid immunotherapy dominance—echoing Formula's original mission to democratize access to transformative cancer treatments.[1][2]
